Catalent, Inc. (NYSE:CTLT) Holdings Trimmed by TD Asset Management Inc

TD Asset Management Inc lessened its holdings in Catalent, Inc. (NYSE:CTLT - Free Report) by 11.1% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 989,418 shares of the company's stock after selling 123,358 shares during the quarter. TD Asset Management Inc owned 0.55% of Catalent worth $44,455,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also recently modified their holdings of CTLT. Norges Bank bought a new stake in shares of Catalent during the 4th quarter valued at about $116,021,000. Cadian Capital Management LP boosted its stake in Catalent by 91.0% during the third quarter. Cadian Capital Management LP now owns 5,304,784 shares of the company's stock worth $241,527,000 after acquiring an additional 2,526,750 shares in the last quarter. Ameriprise Financial Inc. boosted its stake in Catalent by 65.9% during the third quarter. Ameriprise Financial Inc. now owns 3,483,494 shares of the company's stock worth $158,601,000 after acquiring an additional 1,384,313 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its stake in Catalent by 50.6% during the third quarter. Charles Schwab Investment Management Inc. now owns 1,536,313 shares of the company's stock worth $69,948,000 after acquiring an additional 516,464 shares in the last quarter. Finally, Dimensional Fund Advisors LP boosted its stake in Catalent by 29.9% during the fourth quarter. Dimensional Fund Advisors LP now owns 1,639,197 shares of the company's stock worth $73,655,000 after acquiring an additional 376,931 shares in the last quarter.

Catalent Price Performance

Shares of NYSE CTLT traded up $0.19 during midday trading on Friday, reaching $53.80. The stock had a trading volume of 3,415,869 shares, compared to its average volume of 2,324,844. The stock has a 50-day moving average of $55.87 and a 200-day moving average of $51.27. The company has a debt-to-equity ratio of 1.37, a quick ratio of 1.77 and a current ratio of 2.51. The company has a market capitalization of $9.74 billion, a price-to-earnings ratio of -8.82, a price-to-earnings-growth ratio of 5.75 and a beta of 1.18. Catalent, Inc. has a 12-month low of $31.80 and a 12-month high of $60.20.

Catalent (NYSE:CTLT - Get Free Report) last announced its quarterly earnings data on Wednesday, May 8th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.21 by ($0.36). The firm had revenue of $1.07 billion during the quarter, compared to analysts' expectations of $1.11 billion. Catalent had a negative return on equity of 2.73% and a negative net margin of 26.61%. As a group, research analysts anticipate that Catalent, Inc. will post 0.31 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on the stock. Royal Bank of Canada reissued a "sector perform" rating and set a $63.50 price objective on shares of Catalent in a research note on Tuesday, February 20th. StockNews.com initiated coverage on shares of Catalent in a research note on Wednesday. They issued a "sell" rating on the stock. UBS Group reiterated a "neutral" rating and issued a $63.50 target price (up previously from $58.00) on shares of Catalent in a research note on Tuesday, February 6th. Finally, Stephens reiterated an "equal weight" rating and issued a $63.50 target price on shares of Catalent in a research note on Thursday, April 4th. Two equities research analysts have rated the stock with a sell rating, eight have issued a hold rating and three have given a buy rating to the stock. According to MarketBeat.com, Catalent has an average rating of "Hold" and an average price target of $53.14.

Catalent Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.